A PHASE II EVALUATION OF TRABECTEDIN IN THE TREATMENT OF ADVANCED, PERSISTENT, OR RECURRENT UTERINE LEIOMYOSARCOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY

OBJECTIVE: To estimate activity and safety of trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (1 cycle) in uterine leiomyosarcoma. METHODS: Patients with chemotherapy naive, advanced, persistent or recurrent uterine leiomyosarcoma, acceptable organ function and PS ≤ 2 were eligible. A two-stage...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gynecol Oncol
Egile Nagusiak: Monk, Bradley J., Blessing, John A., Street, Daron G., Muller, Carolyn Y., Burke, James J., Hensley, Martee L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497524/
https://ncbi.nlm.nih.gov/pubmed/21996263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2011.09.019
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak